The FDA cleared C2N Diagnostics' PrecivityAD2 on Aug. 20, 2026 for adults age 40 and older with signs or symptoms of cognitive impairment. AJMC reported on Sept.
14, 2026 that it is the first Alzheimer's blood test cleared for that young age group AJMC report. PrecivityAD2 is a blood test that helps show whether memory symptoms may involve brain amyloid-plaque pathology. It is an aid to a clinician's evaluation, not a diagnosis by itself. Patients can bring focused questions about symptoms, history, follow-up testing, and next steps.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from Washu — Use this primary source to verify the official guidance.
- Read the official guidance from Ajmc — Use this primary source to verify the official guidance.
Table of Contents
- Who is this test for?
- What does one blood draw measure?
- How does it fit a primary-care visit?
- What questions can you bring?
- What limits should you understand?
Who is this test for?
The clearance covers adults 40 and older who already have cognitive signs or symptoms. That means new forgetfulness, confusion, word-finding trouble, or changes noticed by family. It does not cover routine checks for people with no symptoms.
This age cutoff matters for young-onset concerns. People in their 40s and 50s often face delays before evaluation. Earlier primary-care review can speed referral, care planning, and treatment discussion.
What does one blood draw measure?
WashU Medicine explains that the test uses high-resolution mass spectrometry to measure amyloid-beta 42/40 plus p-tau217 ratios WashU Medicine summary. Amyloid-beta and p-tau217 are blood markers linked to Alzheimer's pathology. Mass spectrometry is a lab method that identifies tiny protein fragments by weight.
The results are combined as the Amyloid Probability Score 2. A higher score means amyloid plaques are more likely present in the brain. A lower score means they are less likely.
How does it fit a primary-care visit?
Medical News Today notes the test is cleared only alongside history, exam, cognitive testing, and clinician judgment Medical News Today report. It is not a stand-alone diagnosis. It is also not a general screening test for asymptomatic people.
Validation studies reported over 90 percent accuracy for amyloid pathology, described as about 92 percent sensitivity and 96 percent specificity. That performance is comparable to costlier PET scans or spinal-tap spinal fluid testing. In a 1,310-patient study with 165 physicians, primary-care accuracy rose from 65 percent to 93 percent after seeing results.
What questions can you bring?
Bring a short symptom record and ask how it fits your history. Useful questions include: Ask who will order the test and where blood will be drawn.
C2N said the FDA-cleared kit is expected later in 2026, while its lab version remains available through C2N's lab by licensed-provider order. Your clinic can explain current ordering and follow-up timing.
- Could my symptoms qualify me for amyloid blood testing under the clearance?
- What history, exam, and thinking tests will you do alongside the blood test?
- If results suggest amyloid pathology, will you order confirmatory testing or refer me?
- What care plan, safety steps, and treatment discussion come next?
What limits should you understand?
Alzheimer's Association guidance recommends blood-biomarker testing only for symptomatic patients under clinician supervision. There is no endorsement for asymptomatic screening and no primary-care protocol yet established. Social posts that promise simple at-home answers overstate the test.
A positive aid-result still needs clinical context. A negative result does not explain every cause of memory change. Ask what other causes, medicines, sleep issues, mood changes, or referrals your clinician will still review.
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Primary Care Patients Should Know About the News
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Primary Care Patients Should Know About the News
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: How Younger-Onset Alzheimer’s Families Can Compare Testing Options
